Send to

Choose Destination
See comment in PubMed Commons below
J Med. 2004;35(1-6):151-62.

Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.

Author information

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.


To evaluate the efficacy of the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine in treating depression in the menopausal transition and to compare their efficacy, safety, side-effect profiles and drug compliance. One hundred and five perimenopausal patients (51.3 +/- 2.5 yr of age) were randomly assigned to receive a dosage of 50 mg/day of fluvoxamine (n=53) or 20 mg/day of paroxetine (n=52). The visual analog scale (VAS), Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores were evaluated before and after 3 months of therapy in the two groups of women. Significant reduction in HAM-D and HAM-A scores was observed in both groups of women, without significant difference between the two groups. VAS score in the fluvoxamine group (-62.6 +/- 5.2%) was significantly lower than that in the paroxetine group (-51.1 +/- 4.3%) (P < 0.0001). Although fluvoxamine compares favourably with paroxetine in rate of reduction of VAS score, this study suggests that both SSRIs are effective for and tolerated in depressed perimenopausal outpatients.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center